Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.

Moreno-Sanz G, Barrera B, Guijarro A, d'Elia I, Otero JA, Alvarez AI, Bandiera T, Merino G, Piomelli D.

Pharmacol Res. 2011 Oct;64(4):359-63. doi: 10.1016/j.phrs.2011.07.001. Epub 2011 Jul 7.

2.

Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.

Moreno-Sanz G, Barrera B, Armirotti A, Bertozzi SM, Scarpelli R, Bandiera T, Prieto JG, Duranti A, Tarzia G, Merino G, Piomelli D.

Pharmacol Res. 2014 Sep;87:87-93. doi: 10.1016/j.phrs.2014.06.004. Epub 2014 Jun 30.

3.

Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.

Moreno-Sanz G, Sasso O, Guijarro A, Oluyemi O, Bertorelli R, Reggiani A, Piomelli D.

Br J Pharmacol. 2012 Dec;167(8):1620-8. doi: 10.1111/j.1476-5381.2012.02098.x.

5.

Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.

Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, Armirotti A, Moreno-Sanz G, Reggiani A, Piomelli D.

Pharmacol Res. 2012 May;65(5):553-63. doi: 10.1016/j.phrs.2012.02.012. Epub 2012 Mar 7.

6.

Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.

Moreno-Sanz G, Duranti A, Melzig L, Fiorelli C, Ruda GF, Colombano G, Mestichelli P, Sanchini S, Tontini A, Mor M, Bandiera T, Scarpelli R, Tarzia G, Piomelli D.

J Med Chem. 2013 Jul 25;56(14):5917-30. doi: 10.1021/jm4007017. Epub 2013 Jul 3.

7.

Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.

Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D.

Nat Neurosci. 2010 Oct;13(10):1265-70. doi: 10.1038/nn.2632. Epub 2010 Sep 19.

8.

The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).

González-Sarrías A, Miguel V, Merino G, Lucas R, Morales JC, Tomás-Barberán F, Alvarez AI, Espín JC.

J Agric Food Chem. 2013 May 8;61(18):4352-9. doi: 10.1021/jf4007505. Epub 2013 Apr 24.

PMID:
23586460
9.

In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).

Meyer zu Schwabedissen HE, Kroemer HK.

Handb Exp Pharmacol. 2011;(201):325-71. doi: 10.1007/978-3-642-14541-4_9. Review.

PMID:
21103975
11.

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Daood M, Tsai C, Ahdab-Barmada M, Watchko JF.

Neuropediatrics. 2008 Aug;39(4):211-8. doi: 10.1055/s-0028-1103272. Epub 2009 Jan 22.

12.

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF.

Clin Cancer Res. 2011 Jan 1;17(1):89-99. doi: 10.1158/1078-0432.CCR-10-1934. Epub 2010 Nov 18.

13.

Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model.

Wassermann L, Halwachs S, Baumann D, Schaefer I, Seibel P, Honscha W.

Arch Toxicol. 2013 Sep;87(9):1671-82. doi: 10.1007/s00204-013-1066-9. Epub 2013 May 8.

PMID:
23652544
14.

The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

Holland ML, Lau DT, Allen JD, Arnold JC.

Br J Pharmacol. 2007 Nov;152(5):815-24. Epub 2007 Oct 1.

15.

Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.

Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y.

Drug Metab Dispos. 2007 Oct;35(10):1873-9. Epub 2007 Jul 16.

16.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.

Invest New Drugs. 2013 Oct;31(5):1125-35. doi: 10.1007/s10637-013-9923-1. Epub 2013 Jan 13. Erratum in: Invest New Drugs. 2013 Jun;31(3):800.

PMID:
23315030
17.

Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.

Wang L, Leggas M, Empey PE, McNamara PJ.

Drug Metab Dispos. 2012 May;40(5):1024-31. doi: 10.1124/dmd.111.041616. Epub 2012 Feb 21.

18.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Invest New Drugs. 2014 Dec;32(6):1083-95. doi: 10.1007/s10637-014-0143-0. Epub 2014 Jul 31.

PMID:
25078948
19.

The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.

An G, Gallegos J, Morris ME.

Drug Metab Dispos. 2011 Mar;39(3):426-32. doi: 10.1124/dmd.110.035212. Epub 2010 Dec 7.

20.

The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.

Clin Cancer Res. 2002 Jan;8(1):22-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk